To date, the FDA has identified more than 40 patients who received infusions of the Wallcur simulated saline products after an alert was issued in early January. Many patients have reported experiencing fever, chills, tremors and headaches.
Since beginning the investigation, the FDA has reached out to other companies that market simulated products for training purposes to make them aware of this incident and ensure steps were taken to remedy any potentially confusing situations between training products and real drugs.
More articles on the FDA:
IBM lobbies Congress to ease FDA regulations on Watson
FDA provides clearance for Roche MRSA/SA test
FDA approves meningococcal disease vaccine
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
